A Phase 1 interventional study of Placebo and IBI3032 tablets in Part A: Healthy Part B: Overweight or Obesity, sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center). Completed at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Innovent Biologics Technology Limited (Shanghai R&D Center) (part of Innovent Biologics, Inc.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Obesity by Innovent Biologics, Inc. — 5 open to participants now, 9 under way, 4 of them phase 3. Obesity · Innovent Biologics, Inc..
Among the 16 studies in Obesity by Innovent Biologics, Inc., this one is the 12th largest by enrollment, is one of 6 that started in 2025, is one of 6 in phase 1, and was the 11th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →5 of the 16 studies in Obesity by Innovent Biologics, Inc. are open now, in 1 country. Recruiting first, the newest first:
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–65
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18–55 · Healthy volunteers
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18+
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 12–18
Innovent Biologics (Suzhou) Co. Ltd. · Sites in China
Ages 18+
By country, each count listing its studies:
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 4 · Phase 3 6
First in 2020; this study’s year is marked. 6 started in 2025.
This study's enrollment of 80 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 135 across the 16 interventional studies. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Innovent Biologics Technology Limited (Shanghai R&D Center), one of the names counted as Innovent Biologics, Inc.. Under that name alone:
Innovent Biologics Technology Limited (Shanghai R&D Center) is the lead sponsor of 7 studies on the registry; 2 are open to participants now.
3 of the studies in Obesity by Innovent Biologics, Inc. that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06931028Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2 | 2027-05-07 |
| NCT07255209Phase 3Innovent Biologics (Suzhou) Co. Ltd.A Study of IBI362 in Chinese Adolescents With Obesity or Overweight | 2027-10-31 |
| NCT07793019Innovent Biologics (Suzhou) Co. Ltd.IBI3042 Study in Healthy Participants and Overweight or Obese Participants | 2027-09-06 |
Add all 3 to your calendar (.ics) → With an account.
Among the 16 studies in Obesity by Innovent Biologics, Inc., from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part A
Drug: IBI3032 tablets
Part A
Drug: Placebo
Part B
Drug: IBI3032 tablets
Part B
Drug: Placebo
Single dose placebo IBI3032 administered orally
Single dose of IBI3032 administered orally
Number of Participants with adverse events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
Time frame: Part A: Baseline up to Day 15
Number of Participants with adverse events (AEs)
An adverse event (AE) is defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related.
Time frame: Part B: Baseline up to Day 43
Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Part A: Baseline up to Day 15
Number of Participants with One Serious Adverse Event(s) Considered by the Investigator to be Related to Study Drug
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Part B: Baseline up to Day 43
Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Part A: Baseline up to Day 15
Number of Participants with More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug
A summary of other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
Time frame: Part B: Baseline up to Day 43
Under the Serum Concentration-time Curve (AUC) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.
Time frame: Part A: Predose up to 168 hours postdose
Under the Serum Concentration-time Curve (AUC) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.
Time frame: Part B: Predose up to 168 hours postdose
maximum concentration (Cmax) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.
Time frame: Part A: Predose up to 168 hours postdose
maximum concentration (Cmax) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.
Time frame: Part B: Predose up to 168 hours postdose
time to maximum concentration (Tmax) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.
Time frame: Part A: Predose up to 168 hours postdose
time to maximum concentration (Tmax) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.
Time frame: Part B: Predose up to 168 hours postdose
clearance (CL) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.
Time frame: Part A: Predose up to 168 hours postdose
clearance (CL) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.
Time frame: Part B: Predose up to 168 hours postdose
apparent volume of distribution (V) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.
Time frame: Part A: Predose up to 168 hours postdose
apparent volume of distribution (V) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.
Time frame: Part B: Predose up to 168 hours postdose
elimination half-life (T1/2) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of a single dose of IBI3032 in healthy participants.
Time frame: Part A: Predose up to 168 hours postdose
elimination half-life (T1/2) of IBI3032
To evaluate the pharmacokinetic (PK) characteristics of multiple doses of IBI3032 in participants with overweight or obesity.
Time frame: Part B: Predose up to 168 hours postdose
Ran from Sep 2025 to primary completion in Aug 2026, 11 months.
Of 335 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 11 months is above that.
Counting every sponsor, half of 440 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: IBI3032
Innovent Biologics Technology Limited (Shanghai R&D Center) →